Bristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line lung cancer market dominated by rival Merck & Co.
Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal
Bristol-Myers Squibb has agreed a $74 billion deal to merge with Celgene in a deal that will boost its presence in oncology and immunology and make it the fourth-largest drugmaker.
After protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA to Japan’s Taisho Pharma in a $1.6 billion deal
Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to
The latest version of Google DeepMind and Isomorphic Labs’ AlphaFold model can predict the structure and relationships not only of proteins, but “all of life’s molecules”,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.